By Larry Buhl
A triumphant mood was evident at a session of the 12th International AIDS Society (IAS) Conference on HIV Science during which a panel of presenters and experts discussed data from the REPRIEVE clinical trial, which indicated that a common statin medication significantly reduced excess risk of cardiovascular disease (CVD) among people living with HIV.
Read the full article here.
